

1961 3.2.4.2 *Approach*

1962

1963 3.2.4.2.1 *General chapter*

1964

1965 The general testing methods and other specifications which are common in the  
1966 monographs may be reflected in a General chapter of herbal monographs. It may give an  
1967 account of tests/procedures or analytical techniques and of general principles. General  
1968 chapters may contain the following, but are not limited to:

1969

1970 i. general testing methods that include equipments, procedures, methods and limits,  
1971 etc. for application through individual monographs;

1972 ii. information for the interpretation of the monographs;

1973 iii. sampling procedures;

1974 iv. macroscopic, microscopic, powder microscopy characters;

1975 v. contaminants tests, e.g. foreign organic matter, heavy metals, aflatoxins,  
1976 microbial contaminants;

1977 vi. physicochemical tests, e.g. extractable values, ash values;

1978 vii. TLC/HPTLC and LC fingerprint for identification;

1979

1980 When a general chapter is referenced in a monograph, acceptance criteria may be  
1981 presented.

1982

1983 3.2.4.2.2 *Individual herbal monographs*

1984

1985 The herbal drug monograph in pharmacopoeias may include crude herbs, processed herbs,  
1986 herbal formulations, etc., that contain as active ingredients parts of plants, or other plant  
1987 materials, or combinations.

1988

1989

1990 3.2.4.2.2.1 *Crude herbs*

1991

1992 Crude plant material is, e.g. leaves, flowers, fruit, seed, stems, wood, bark, roots,  
1993 rhizomes or other plant parts, which may be entire, fragmented or powdered. Herbs are  
1994 usually in dried form, but sometimes when specified may also be in a fresh form. In  
1995 specific cases exudates which have not been processed further are also covered under the  
1996 term herbs.

1997

1998 3.2.4.2.2.2 *Processed herbs*

1999

2000 Processed herbs means preparations obtained by subjecting herbs to treatment such as  
2001 extraction, distillation, expression, fractionation, purification, concentration and partial or  
2002 full fermentation. The basis for finished herbal preparations includes comminuted or  
2003 powdered herbal materials, or extracts, tinctures and fatty oils of herbal materials. They  
2004 also include preparations made by steeping or heating herbal materials in alcoholic  
2005 beverages and/or honey, or in other materials.

2006

2007 3.2.4.2.2.3 *Herbal formulations*

2008

2009 Herbal preparations made from one or more herbs. If more than one herb is used, the term  
2010 “mixture herbal product” can also be used. Finished herbal products and mixture herbal  
2011 products may contain excipients in addition to the active ingredients. However, finished  
2012 products or mixture products to which chemically-defined active substances have been  
2013 added, including synthetic compounds and/or isolated constituents from herbal materials,  
2014 are not considered to be herbal.

2015

2016 3.2.4.3 *Monograph development*

2017

2018 The following concepts are important in the development and setting of specifications  
2019 and may be provided for each herbal monograph. The monograph should include:  
2020 Authorized Title, Definition, Limits of active ingredients, Marker compounds,

2021 Description, Category, Identification, Physicochemical tests and Assay of the marker  
2022 constituents, Contaminants, Specific tests and Additional requirements.

2023

2024 *3.2.4.3.1 Monograph title*

2025

2026 For monographs intended for inclusion in pharmacopoeias, the title of the monograph  
2027 may include the Latin binomial nomenclature or Synonym or Common name or  
2028 Traditional/Colloquial name, whichever is appropriate, and is followed by the name of  
2029 plant part(s) or plant product (e.g. resin, gum-resin) and where applicable the processed  
2030 form.

2031

2032 *3.2.4.3.2 Definition*

2033

2034 Some or all of the following are usually included in the definition:

- 2035 • the state of the drug: whole, fragmented, peeled, cut, fresh or dried;
- 2036 • the complete scientific name of the plant (genus, species, subspecies, variety,  
2037 author); commonly used synonyms may be mentioned;
- 2038 • the part or parts of the plant used;
- 2039 • where appropriate, the stage in the growth-cycle when harvesting takes place, or  
2040 other necessary information;
- 2041 • wherever possible, the minimum content of quantified constituents (either  
2042 responsible for the biological activity of the herb (bio-marker) or a chemical  
2043 compound known to be present in the herb even if not responsible for biological  
2044 activity (chemical/analytical marker);
- 2045 • herbal drugs very often contain a mixture of related substances, in which case the  
2046 total content of quantified constituents is determined and expressed as one of the  
2047 constituents, usually the major constituent; separate limits may be given for  
2048 different forms of the drug (whole/cut).

2049

2050

2051 3.2.4.3.3 *Characters*

2052

2053 This section may contain a brief description of the organoleptic characters of the drug  
2054 such as colour, odour, taste, etc.

2055

2056 3.2.4.3.4 *Category*

2057

2058 It includes the therapeutic category to which the Title of the monograph belongs.

2059

2060 3.2.4.3.5 *Identification*

2061

2062 The purpose of the Identification category of a monograph is to ensure that the article  
2063 under examination is in agreement with what is stated in the Definition of the article. All  
2064 the identifications mentioned below are not necessarily included: some may be absent  
2065 when they are not feasible or are not significant for the purpose of identification.  
2066 Macroscopic requirements with appropriate scale (such as grid scale) and microscopic  
2067 requirements of an herbal monograph should be provided with histological characters and  
2068 colour photographs.

2069

2070 3.2.4.3.5.1 *Macroscopic characters*

2071

2072 The important macroscopic botanical characters of the drug are specified to permit a clear  
2073 identification. A detailed coloured photograph should be provided. When two  
2074 species/subspecies of the same plant are included in the definition, the individual  
2075 differences between them are indicated.

2076

2077 3.2.4.3.5.2 *Microscopic characters*

2078

2079 It involves gross microscopic examination of the drug and it can be used to identify the  
2080 organized/unorganized drugs by their known histological characters. It is mostly used for  
2081 qualitative evaluation of organized, crude drugs in entire and powder forms with the help

2082 of a microscope. Using a microscope various cellular tissues and their arrangements such  
2083 as trichomes, stomata, starch granules and calcium oxalate crystals, etc. can be detected.  
2084 Crude drug can also be identified microscopically by cutting the thin TS (transverse  
2085 section)/LS (longitudinal section) and appropriately mounting the slide (example, in case  
2086 of wood). Quantitative aspects of microscopy include study of stomatal number and  
2087 index, palisade ratio, vein-islet number, size of starch grains and length of fibres, etc.

2088

#### 2089 3.2.4.3.5.3 *Fingerprinting*

2090

2091 Chromatographic or spectroscopic patterns, sometimes referred to as “fingerprints”, may  
2092 be used as standards for identification, though they may not be mandatory. These  
2093 fingerprints can be obtained by HPLC, UHPLC, CE, GC, TLC/HPTLC, IR, mass  
2094 spectroscopy, etc. Such fingerprints may be suitably referenced within the pharmacopoeia.  
2095 The fingerprints must be able to distinguish these materials from other materials with  
2096 potential for species substitution and suspected adulteration. The acceptance criteria for  
2097 identification tests using chromatographic methods such as HPLC, UHPLC, CE or GC  
2098 methodology must contain a description of the critical features of the fingerprint  
2099 chromatograms such as the presence of specified peaks, retention time, their order of  
2100 elution, and where possible, their relative abundance. For methods of TLC/HPTLC,  
2101 description must include colour and position of the characteristic bands. A colour image  
2102 of a typical HPTLC chromatogram should be provided as a guide for the users of the  
2103 monographs though not as a part of the monograph which may have legal connotations.  
2104 A critical aspect of the identification of herbal materials by separation techniques is the  
2105 use of reference standards because they provide assignment at the time of use. In addition  
2106 to the sample solution, a standard solution containing the reference standard is  
2107 chromatographed concomitantly. The reference material used in the preparation of a  
2108 standard solution may be an authenticated Botanical Reference Substance (BRS), a  
2109 reference standard extract, a single chemical entity or a standardized mixture of  
2110 substances.

2111

2112 DNA-based identification test may be provided in order to improve authentication of  
2113 botanical identity, especially in those cases where there is controversial botany or  
2114 chances of substitution/adulteration.

2115

#### 2116 3.2.4.3.6 Tests

2117

2118 The following tests are indicated to be carried out. Other appropriate tests specific to the  
2119 material under examination, if required, may be carried out.

2120

#### 2121 3.2.4.3.6.1 Physicochemical evaluation

2122

2123 Physicochemical evaluation is an important parameter in detecting adulteration or  
2124 improper handling of drugs. It can serve as a valuable source of information and provide  
2125 an appropriate standard to establish the quality of herbs. These are:

2126

- extractable matter:

2127

it is considered useful to determine extractable matter only in herbal drugs where  
2128 no constituent suitable for an assay is known or where the material is used to  
2129 produce a preparation with a dry residue;

2130

- total ash:

2131

this test is always included unless otherwise justified. It is to be carried out on  
2132 the powdered drug;

2133

- acid-insoluble ash:

2134

this test may be carried out depending on the nature of the particular herbal drug  
2135 and is used to detect unacceptable quantities of certain minerals.

2136

#### 2137 3.2.4.3.6.2 Loss on drying

2138

2139 Herbal drugs are dried for preservation purposes, if they are insufficiently dried, growth  
2140 of yeasts or moulds may occur. It is the loss of weight expressed as percentage w/w  
2141 resulting from water and volatile matter of any kind that can be driven off under

2142 specified conditions. The limit is specified on the basis of the results obtained on a  
2143 reasonable number of varied samples of acceptable quality.

2144

2145 *3.2.4.3.6.3 Swelling index*

2146

2147 Applicable to certain hydrocolloid-containing herbal drugs.

2148

2149 *3.2.4.3.6.4 Bitterness values*

2150

2151 Applicable to herbal drugs containing bitter principles.

2152

2153 *3.2.4.3.6.5 Contaminants – general*

2154

2155 *3.2.4.3.6.5.1 Foreign organic matter*

2156

2157 It is the material consisting of any or all of the following:

- 2158 • parts or organs of plant from which the drug is derived other than the parts/organs  
2159 named in the definition and description or for the limit is prescribed in the  
2160 individual monograph;
- 2161 • any part or organs of plant other than those named in the definition and  
2162 description;
- 2163 • matter not coming from the source ;
- 2164 • moulds, insects or other animal contaminant.

2165

2166 Generally a limit of 2% of foreign matter is imposed, unless otherwise prescribed in a  
2167 specific monograph. Where a limit for foreign matter greater than 2% is to be prescribed,  
2168 it is stated in the specific monograph with an indication of the type of foreign matter.

2169 Where necessary, the monograph should indicate how the foreign matter is identified.

2170

2171

2172 3.2.4.3.6.5.2 *Heavy metals*

2173

2174 The test is prescribed where there is the potential for contamination by heavy metals.

2175 The limit of heavy metals is indicated in the individual monograph in terms of ppm, i.e.

2176 the parts of lead per million parts of the substance under examination.

2177

2178 3.2.4.3.6.5.3 *Microbial contamination*

2179

2180 The pharmacopoeial monographs should specify the total count of aerobic

2181 microorganisms, the total count of yeasts and moulds and the absence of specific

2182 pathogenic bacteria (e.g. *Staphylococcus aureus*, *Escherichia coli*, *Pseudomonas*

2183 *aeruginosa*, *Shigella* and *Salmonella* species)

2184

2185 3.2.4.3.6.5.4 *Aflatoxins*

2186

2187 Aflatoxins are one of the most toxic classes of mycotoxins; they arise from the growth of

2188 many species of *Aspergillus*, a fungus. Wherever fungal contamination of the herbal

2189 article is likely, it is advisable to include a test for aflatoxins.

2190

2191 3.2.4.3.6.6 *Contaminants – specific*

2192

2193 An individual herbal monograph may require certain specifications that are peculiar to

2194 that monograph, especially when safety is an issue. Limits may be set in certain specific

2195 monographs for the characters that are undesirable or have negative botanic

2196 characteristics. When one desires a limit for harmful substances that are present either

2197 naturally in the substance or formed as a result of post-harvest processing practices, such

2198 submissions must be accompanied by toxicity data.

2199

2200



2201 3.2.4.3.7 *Assay*

2202

2203 Wherever possible, an assay is included. Assay is carried out using suitable instruments  
2204 such as UV spectrophotometer, LC, GC or by HPTLC, etc., to check and quantify one or  
2205 more markers, specifying either the percentage or relative proportions of them.

2206

2207 3.2.4.3.8 *Additional information*

2208

2209 3.2.4.3.8.1 *Storage*

2210

2211 Storage conditions are applicable unless otherwise specified: Store protected from light.

2212 Where applicable, additional specific conditions are given in the individual monograph.

2213

2214 3.2.4.3.8.2 *Labelling*

2215

2216 Labelling of herbal products includes the label both upon the immediate container and  
2217 other associated labelling and written, printed or graphic materials. The label states the  
2218 Latin binomial followed by the authorized name; the plant part(s), plant product or  
2219 processed form contained in the container or from which the article was derived.

2220 Content, in percentage, of active principles or marker compounds should be stated.

2221 Labelling should be in accordance with the applicable drug laws.

2222

2223 3.2.4.4 *Botanical Reference Substances/Phytochemical Reference Substances*

2224

2225 This section includes list of all authorized BRS/Phytochemical Reference Substances  
2226 (PRS) or biomarkers that are required for comparison to conduct the monograph tests,  
2227 method development and evaluation. These substances are plant parts/isolated  
2228 compounds certified to have come from a plant that have been highly characterized and  
2229 approved by the competent authority.

2230

2231 These substances are used as a reference material for comparison and confirming the  
2232 identity and quantity of herbal samples under examination. Thus, a standard operating  
2233 procedure giving detailed steps for preparation, qualification, validation and revalidation  
2234 may be incorporated. Proper documentation including the certificate of analysis and  
2235 their issuance to the end-users may be done.

2236

2237 An adequate sampling plan of the source material for these substances from different  
2238 locations/seasons may also be suggested to map the “natural window of the chemistry”  
2239 for developing the monographs.

2240

2241 A collaborative ring testing from at least three accredited/certified laboratories should  
2242 be done and the results obtained should be reviewed before assigning or fixing the limits.

2243

2244 [3.2.5 *Monographs on other products*] Action: on hold, to be discussed later]

2245

#### 2246 4. REFERENCE STANDARDS

2247 [Argentinian Pharmacopoeia, BP, IPC, USP, WHO]

2248

2249 4.1 Reference substances are referred to in pharmacopoeias. They are an integral part  
2250 of the procedures in a pharmacopoeia, and their use demonstrates compliance with  
2251 the corresponding documentary standard. They constitute authenticated  
2252 benchmarks for those analytical tests and assays that are based on comparison of  
2253 the certified attribute(s) of a sample with those of the reference standard. They  
2254 enable the analyst to achieve accurate and traceable results. In particular,  
2255 reference substances are used to identify, to determine the purity or to assay  
2256 pharmaceutical substances and preparations. They are further used to verify the  
2257 performance of test methods or to calibrate analytical instruments.

2258

2259 Maintenance of a collection of pharmacopoeial reference materials requires  
2260 ongoing effort. This effort includes continued suitability-for-use studies, stability

- 2261 studies, addition of new reference materials for new monographs and monographs  
2262 that are being updated, and studying candidate materials for replacement lots.  
2263
- 2264 4.2 Reference substances may be fully characterized by physical or chemical means  
2265 alone, or may require the use of biological- or microbiological tests. The  
2266 characterization of reference substance by biological and microbiological methods  
2267 may follow special rules, which are not yet fully covered in this chapter.  
2268
- 2269 4.3 The pharmacopoeial authority should apply appropriate principles during the  
2270 establishment, storage and distribution of reference substances to guarantee that  
2271 they are suitable for their intended use. All operations should be carried out under  
2272 a defined quality management system. It is desirable that the quality management  
2273 system be assessed as satisfactory by an independent body.  
2274
- 2275 4.4 Source material for the establishment of reference substances may be synthesized  
2276 and purified for this purpose or may be selected from the pharmaceutical  
2277 production of the substance referred to in the monograph provided that the purity  
2278 and homogeneity are suitable. In some cases, for example, in order to improve the  
2279 stability of the reference substance, it may be useful to select an alternative salt  
2280 (or salt vs base), solvate or hydrate.  
2281
- 2282 4.5 The source material should be tested with suitable analytical techniques aiming to  
2283 characterize all relevant quality attributes. The identity is confirmed and the purity  
2284 is determined usually based on results obtained with the validated methods of the  
2285 respective monographs. However, the use of further analytical techniques may be  
2286 appropriate in order to fully characterize the candidate material. Absolute methods  
2287 (for example, volumetric titrations, differential scanning calorimetry) may be  
2288 employed to complement and verify the results of relative methods, where  
2289 appropriate.  
2290

- 2291 4.6 The extent of testing and the number of laboratories involved in characterizing the  
2292 material depend on the intended use of the reference substance to be established.  
2293 If required, assay standards are characterized in interlaboratory trials to better  
2294 estimate the trueness of the assigned value or to determine the associated  
2295 uncertainty.  
2296
- 2297 4.7 A thorough purity investigation of the candidate material is usually performed  
2298 with the aim to identify and quantify all relevant components (i.e. main  
2299 component, organic and inorganic impurities, water and residual solvents). The  
2300 cumulative percentage of all quantified components should yield 100% (mass  
2301 balance approach).  
2302
- 2303 4.8 The content assigned to a quantitative reference standard depends on the purity of  
2304 the candidate material and is specific to the method for which the standard will  
2305 serve as a reference.  
2306
- 2307 4.9 Reference standards are dispensed into suitable containers under appropriate  
2308 filling and closure conditions, to ensure the integrity of the reference material. The  
2309 containers employed should minimize the risk of decomposition, contamination  
2310 and moisture uptake.  
2311
- 2312 4.10 The labelling should provide all information necessary to use the reference  
2313 substance as intended, i.e. the name of the reference substance, the batch number,  
2314 storage conditions, etc. If intended for quantification the assigned content is also  
2315 given. An accompanying leaflet may be considered to be part of the labelling.  
2316
- 2317 4.11 Reference substances should be stored in their packaging and distributed under  
2318 conditions suitable to ensure their stability.  
2319
- 2320 4.12 The stability of reference standards stored for distribution is monitored regularly.  
2321 The frequency and extent of the reexaminations are based on the:

- 2322           •     liability of the reference standard to degradation;
- 2323           •     container and closure system;
- 2324           •     storage conditions;
- 2325           •     hygroscopicity;
- 2326           •     physical form;
- 2327           •     intended use.

2328   4.13   The analytical methods employed to verify the stability are often chosen among  
2329           those performed during the establishment of the reference standard. The  
2330           maximum permitted deviation from the assigned value should be predefined and,  
2331           if exceeded, the batch should be reestablished or replaced.

2333   4.14   When reference substances are used for purposes other than those for which they  
2334           were established, the responsibility for assessing the suitability rests with the user  
2335           or the authority that prescribes or authorizes this use.

2337   4.15   Infrared reference spectra may be provided for use in identification test as  
2338           described in monographs of pharmacopoeias.

2340   4.16   Pharmacopoeial reference materials should be made available to the public  
2341           without restriction, other than as required to comply with laws specifically  
2342           regulating the shipment or export of certain materials.

## 2344   5.     ANALYTICAL TEST PROCEDURES AND METHODOLOGIES

### 2345           (ANALYTICAL METHOD) [IPC]

2346           Analytical test procedures and methodologies are employed to establish the identity,  
2347           purity, impurity, strength, quality and potency of drug substances and drug products. An  
2348           analytical method mentioned in a pharmacopoeia should be simple, reliable, accurate,  
2349           sensitive and specific.

2351

2352 A pharmacopoeia provides physical, physicochemical, chemical, pharmaceutical and  
2353 biological methods for analysis of quality of drug substances (APIs) and drug products  
2354 (finished dosage forms). The type of method applied for analysis depends on the nature  
2355 of the drug.

2356

2357 The principles of method validation apply to all types of analytical procedures. It is  
2358 established by demonstrating documentary evidence with respect to any particular drug  
2359 substance or drug product. In certain products like biological, biotechnological, botanical  
2360 or radiopharmaceutical drugs some specifications may not be applicable. For example,  
2361 many bioassays are based on animal challenge models, immunogenicity assessments or  
2362 other immunoassays that have unique features that should be considered.

2363

2364 System suitability testing should be an integral part of analytical method

2365

## 2366 5.1 Types of analytical procedure

2367

### 2368 *5.1.1 Regulatory analytical procedure*

2369

2370 A regulatory analytical procedure is the analytical procedure used to evaluate a defined  
2371 characteristic of the drug substance or drug product. The analytical procedures that are  
2372 legally recognized are the regulatory analytical procedures for compendial items.

2373

### 2374 *5.1.2 Alternative analytical procedure*

2375

2376 An alternative analytical procedure is an analytical procedure that is not a regulatory  
2377 analytical procedure. A proper validation of the alternative analytical procedure should be  
2378 done to show its performance equal to or better than the regulatory analytical procedure.

2379 If an alternative analytical procedure is used, it is necessary to provide a rationale for its  
2380 inclusion and identify its use (e.g. release, stability testing), validation data and  
2381 comparative data to that of regulatory analytical procedure.

2382

2383 *5.1.3 Stability-indicating assay*

2384

2385 A stability-indicating assay is a validated quantitative analytical procedure that can detect  
2386 the changes with time in the pertinent properties of the drug substance and drug product.

2387 A stability- indicating assay accurately measures the active ingredients, without  
2388 interference from degradation products, process impurities, excipients or other potential  
2389 impurities.

2390

2391 *5.2 Validation of analytical methods*

2392

2393 It is the process of demonstrating that analytical procedures are suitable for their intended  
2394 use. The methods validation process for analytical procedures begins with the planned  
2395 and systematic collection of the validation data to support the analytical procedures. A  
2396 full validation report should be generated and any deviation/change during the process  
2397 should be justified and approved. All analytical procedures are of equal importance from  
2398 a validation perspective. In general, validated analytical procedures should be used,  
2399 irrespective of whether they are for in-process, release, acceptance or stability testing.  
2400 Each quantitative analytical procedure should be designed to minimize assay variation.

2401

2402 *5.2.1 Validation characteristics*

2403

2404 The validation of analytical procedures is mentioned in detail in ICH guideline (Q2R1)  
2405 “Validation of Analytical Procedures: Text and Methodology”. Although not all of the  
2406 validation characteristics are needed for all types of tests.

2407

2408 A brief account of the same is as under:

2409 A. **Specificity:** Specificity is the ability to assess unequivocally the analyte in the  
2410 presence of components that may be expected to be present. Typically these should  
2411 include impurities, degradants, matrix, etc.

2412

2413 B. **Linearity:** Linearity of an analytical procedure is its ability (within a given range) to  
2414 obtain test results that are directly proportional to the concentration (amount) of analyte  
2415 in the sample.

2416  
2417 C. **Range:** The range of an analytical method is the interval between the upper and  
2418 lower concentration (amounts) of analyte (including these concentrations) for which it  
2419 has been demonstrated that the analytical procedure should has suitable level of  
2420 precision, accuracy and linearity.

2421  
2422 D. **Accuracy:** Accuracy of an analytical procedure expresses the closeness of an  
2423 agreement between the value which is accepted either as a conventional true value as  
2424 accepted reference value and the value found. This is sometimes termed trueness.

2425  
2426 E. **Precision:** The precision of an analytical procedure expresses the closeness of  
2427 agreement (degree of scatter) between a series of measurements obtained from multiple  
2428 sampling of the same homogeneous sample under the prescribed conditions. Precision  
2429 should be considered at three levels: repeatability, intermediate precision and  
2430 reproducibility.

2431 • **Repeatability (intra-assay precision):** repeatability expresses the precision under  
2432 the same operating conditions over a short interval of time. Repeatability is also termed  
2433 as intra-assay precision.

2434 • **Intermediate precision:** intermediate precision expresses within-laboratory  
2435 variations: different days, different analysts or equipment, etc.

2436 • **Reproducibility:** reproducibility expresses the precision between laboratories  
2437 (collaborative studies, usually applied to standardization of methodology).

2438

2439 F. **Detection limit:** the detection limit of an analytical procedure is the lowest  
2440 concentration of analyte in a sample that should be detected but not necessarily  
2441 quantitated as an exact value.

2442



2443 G. **Quantitation limit:** the quantitation limit of an individual analytical procedure is the  
2444 lowest amount of analyte in a sample which should be quantitatively determined with  
2445 suitable precision and accuracy.

2446  
2447 H. **Robustness:** the robustness of an analytical procedure is a measure of its capacity to  
2448 remain unaffected by small but deliberate variations in method parameters and provides  
2449 an indication of its reliability during normal usage. Such testing should be performed  
2450 during development of the analytical procedure.

2451

2452 *5.2.2 Other method validation information*

2453 Methods validation information should also include:

2454

- 2455 • data to demonstrate the stability of all analytical sample preparations through the  
2456 time required to complete the analysis;
- 2457 • legible reproductions of representative instrument output or recordings (e.g.  
2458 chromatograms) and raw data output (e.g. integrated areas), as appropriate;
- 2459 • instrument output for placebo, standard and sample should also be provided;
- 2460 • representative calculations using submitted raw data, to show how the impurities  
2461 in drug substance are calculated;
- 2462 • information from stress studies;
- 2463 • impurities labeled with their names and location identifiers (e.g. RRT for  
2464 chromatographic data) for the impurity analytical procedure.

2465

2466 *5.2.2.1 Identification*

2467

2468 Identification of drugs may be carried out by IR, differential scanning calorimetry (DSC),  
2469 X-ray diffraction (XRD), UV, LC, TLC/HPTLC, etc., or by applying other suitable  
2470 techniques. A specific identification test should be included for the active ingredient  
2471 whenever possible. In cases where a non-specific identification analytical procedure is  
2472 proposed for the active ingredient, two independent analytical procedures are generally  
2473 sufficient.

2474

2475 *5.2.1.1 Impurities*

2476 The validation characteristics under quantitative testing for impurities apply, regardless  
2477 of which methodology is used to quantitate impurities. If the same analytical procedure is  
2478 proposed as a limit test, validation characteristics under limit testing for impurities will  
2479 apply.

2480

2481 *5.2.1.2 Assay*

2482 Assay includes the content of the active ingredient and measurement of content in  
2483 dissolution and content uniformity of samples.

2484

2485 *5.2.1.3 Specific tests*

2486 Specific tests to control the quality of drug substance, excipient or drug product can  
2487 include tests such as particle size analysis, droplet distribution, spray pattern, dissolution  
2488 (excludes measurement), optical rotation and methodologies such as Raman spectroscopy,  
2489 DSC, etc. The validation characteristics may differ for various analytical procedures.

2490

2491 *5.3 Analytical methodology/analytical procedures*

2492

2493 The quality data can only be generated if all standards, samples, reagents, instruments  
2494 used for the analyses are suitable and each analytical step is performed in a systematic  
2495 manner.

2496

2497 • *Sample preparation*

2498 For the analysis sufficient amount of sample should be available. It should be randomly  
2499 collected. Analytical method designed/selected should be capable of measuring the  
2500 analyte of interest even in presence of interferants (sample matrix, excipients, etc.).

2501

2502 • *Standard preparation*

2503 Procedures for the preparation of all standard solutions (e.g. stock solution, working  
2504 standard solutions, internal standards) should be well documented.

2505

2506       • *Reagent preparation*

2507       There should be a system in place to ensure the quality of reagents. The reagents should  
2508       be obtained only from reputed/accredited suppliers. The supplier should provide  
2509       documentary evidence of any accreditation status. Reagents and solutions should be  
2510       labelled to indicate identity (with concentration if appropriate), expiry date and specific  
2511       storage instructions. Information concerning source, preparation date and stability should  
2512       be available.

2513

2514       Many analytical methods are used in pharmacopoeial monographs. A few widely used  
2515       methods are described below.

2516

2517       *5.3.1 Dissolution test*

2518       In vitro dissolution testing as applied to solid-dosage forms measures the amount of drug  
2519       dissolved in a known volume of liquid medium at a predetermined time, using a specified  
2520       apparatus designed to carefully control the parameters of dissolution testing. It can help  
2521       pinpoint formulations that may present potential bioequivalence problem. Once a  
2522       formulation has been shown to be bioavailable, dissolution testing is of great value in  
2523       assuring lot-to-lot bioequivalence.

2524

2525       Dissolution test is incorporated in pharmacopoeias to give a direction to stakeholders to  
2526       formulate drug dosage forms and to develop quality control specifications for its  
2527       manufacturing process. It applies to tablets and capsules.

2528

2529       The dissolution procedure description and validation should include the following.

2530

2531       *5.3.1.1 Dissolution medium*

2532       Solvent specified in the individual monograph should be used.

2533

2534

2535 *5.3.1.2 Procedure*

2536 A dissolution test consists of a dissolution procedure and method of analysis (automated  
2537 on-line analysis or manual sampling followed by HPLC analysis). The written procedure  
2538 should cover the following items:

- 2539 • Apparatus;
- 2540 • preparation of standard;
- 2541 • preparation of sample;
- 2542 • method of analysis (e.g., UV, HPLC, etc.);
- 2543 • sampling procedure (e.g. intervals, filtration, handling of samples, dilutions);
- 2544 • calculations;
- 2545 • acceptance criteria.

2546

2547 Regardless of the method of analysis, system suitability criteria should be described.

2548

2549 Blank and standard solution spectra or chromatograms should be included.

2550

2551 *5.3.1.3 Acceptance criteria*

2552 In case of solid dosage forms, the pharmacopoeias give a limit:

- 2553 • immediate release typically means that 75% of the API is dissolved within 45  
2554 minutes:
  - 2555 – rapidly dissolving:  $\geq 85\%$  in  $\leq 30$  minutes
  - 2556 – very rapidly dissolving:  $\geq 85\%$  in  $\leq 15$  minutes.

2557

2558 In case of immediate-release dosage forms as per pharmacopoeias, the requirements are  
2559 met if the quantities of active ingredient(s) dissolved from the dosage forms tested  
2560 conform to the following table, unless otherwise specified in the individual monograph.

2561

2562

2563